Earth Science Tech Inc. (ETST) Offers Medical, Industrial

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
684
Earth Science Tech Inc. (ETST) Offers Medical, Industrial Hemp Products as Leader in the CBD Sector

- Earth Science Tech is a biotechnology company offering high-grade cannabinoids
- ETST has diverse subsidiaries that promote the company’s role as a leader in the CBD sector
- Earth Science Tech has various partnerships and distribution agreements in place

Earth Science Tech Inc. (OTCQB: ETST) operates in the hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development fields. A biotechnology company headquartered in Doral, Florida, ETST markets high purity and quality full-spectrum cannabinoids. The company’s wholly owned subsidiaries – including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and Canna Inno Laboratories Inc. – concentrate on developing Earth Science Tech’s role as a worldwide leader in the CBD sector.

The company’s management team consists of experienced industry experts from the nutraceuticals, dietary supplement and life sciences fields. Earth Science Tech is developing new products and has secured several partnerships, with strategic plans to extend its footprint within the medical cannabis market. These partnerships will enable the company to develop new and novel cannabinoid-based pharmaceutical and nutraceutical products (http://nnw.fm/Jz5wk).

Wholly owned subsidiary Earth Science Pharmaceutical develops low-cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and diseases (STIs). The executive team of Earth Science Pharma has years of scientific, medical and business experience in the health, research and manufacturing fields. The subsidiary is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

Earth Science Pharma’s first medical device is MSN-2, a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Tech is advancing clinical testing of MSN-2 via a collaborative agreement with Laboratories BNK Canada (http://nnw.fm/vcA4o).

Wholly owned subsidiary Cannabis Therapeutics is working to take a leadership role in the development of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical products. The company is invested in research and development to explore and harness the medicinal power of cannabidiol. Cannabis Therapeutics is also working to integrate the CBD molecule with existing generic drug molecules. The company’s mission is to help change the health care landscape by introducing its proprietary cannabis/cannabinoid-based products made for the global pharmaceutical and retail consumer markets.

Established in 2017, Canna Inno Laboratories is Earth Science Tech’s Canadian subsidiary, based in Montreal, Québec. The company’s mandate is to give ETST a foothold in Québec and provide the company with access to government grants offered to innovators in the pharmaceutical industry. One grant has been approved so far.

Earth Science Tech’s medical and industrial hemp products are made from high-grade, full-spectrum cannabinoids that are extracted using the supercritical CO2 liquid process. All of the company’s full-spectrum cannabinoids are mixed in coconut MCT oil to ensure the best delivery and absorption, and its offerings include CBD, CBDa, CBG, CBGa, CBN, CBC and CBDV; the cannabinoids also contain terpenoids, aminos, omegas, saponins and flavonoids.

Earth Science Tech has entered into agreements with CannaBiz and Desert Sun Distribution (http://nnw.fm/Q0zqC) for the distribution of the company’s high-grade, full-spectrum cannabinoids line throughout pharmacies, chiropractors, dispensaries, athletic clubs and clinics in the United States.

“We see tremendous synergy between our CBD line and the health care practitioner and pharmacy spaces,” ETST Chief Sales Officer David Barbash stated in a news release. “The distribution agreements with CannaBiz and Desert Sun Distribution, while important, are only a fraction of the opportunities we see for our CBD products.”

Earth Science Tech continues to develop its diverse portfolio and pipeline. The company offers investors the opportunity to be part of the burgeoning cannabinoid-based pharmaceutical and nutraceutical products market as it expands its role as a leader in different sectors. Earth Science Tech remains dedicated to developing leading-edge pharmaceutical and medical device offerings.

For more information, visit the company’s website at www.EarthScienceTech.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Earth Science Tech, Inc. (ETST) Stock Research Links

ETST Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 60

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 19

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 24

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 139

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 11

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 94

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 31

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Artprice News Revolutionizes Global Art Market Information

Updated Category News Views 237

Artprice News Launch: A New Chapter in Art Market Reporting Artprice by Artmarket has introduced a groundbreaking initiative with the launch of Artprice News, marking a significant evolution in the landscape of art market information. This innovative news agency is tailored exclusively for the art world, broadcasting valuable insights in 11 languages and spanning 122...

Continue Reading
U-BX Technology Ltd. Responds to Nasdaq Notification on Listing

Updated Category News Views 211

U-BX Technology Ltd. Responds to Nasdaq Notification U-BX Technology Ltd. (NASDAQ: UBXG), recognized as a frontrunner in offering innovative services powered by artificial intelligence to the insurance sector, recently informed stakeholders regarding important notifications received from The Nasdaq Stock Market LLC. Details of Nasdaq Notification Letters On a recent date,...

Continue Reading
Understanding Investor Rights in Newmont Securities Class Action

Updated Category News Views 370

Understanding the Basics of the Newmont Class Action Investors who have sustained losses exceeding $50,000 in Newmont Corporation should take heed of an active class action. This legal effort aims to provide relief for those affected by adverse developments within the company. Faruqi & Faruqi, LLP, a prominent securities law firm, is at the forefront of this investigation...

Continue Reading
Tarte's Record-Breaking Collab: 60 Seconds to Sellout

Updated Category News Views 129

When Makeup Meets Pajamas: The Perfect Storm Picture this: a makeup brand and a lifestyle label dreaming up a collaboration that sends consumers into a full-blown frenzy. In a whirlwind that lasted just 60 seconds, tarte's latest partnership with Roller Rabbit blazed through stock, cementing its place as a record-breaking phenomenon. Maureen Kelly, tarte’s intrepid CEO,...

Continue Reading
What Lessons Can Traditional Investors Learn From the Rise of Ethereum?

Updated Category Crypto Views 3176

Turn the clock back a few decades, and investors on Wall Street would laugh if you tried to pitch the concept of blockchain to them. It’s one of those ideas that sound like they’d technically work but would be impossible to practically execute. Yet today, blockchain and cryptocurrency exist and are proof that the skeptics were wrong. Sadly, many traditional investors...

Continue Reading